Clinical trials: Placebo Response
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects
A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects.
- Trial name
- NCT02439359
- Testing
- CF-301
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ContraFect
Depressive Disorder, Major
Study of Medication and Placebo Response in Major Depression
The primary purpose of the research study is to use recordings of brain electrical activity (through electroencephalogram, or EEG) and symptom measurements to determine whether patients are likely to show a response to medication…
- Trial name
- NCT00229476
- Testing
- sertraline (Zoloft)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.
This study aims to test the effect of a newly-approved stimulant medication, lisdexamfetamine dimesylate (Vyvanse), on specific residual symptoms of depression found in some patients who are undergoing treatment with, but have…
- Trial name
- NCT01148979
- Testing
- Lisdexamfetamine Dimesylate (Vyvanse)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mclean Hospital
Healthy Volunteer
A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
This study is a phase 1, double-blind, placebo-controlled crossover study of SAGE-718 using a ketamine challenge, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic response using magnetic resonance…
- Trial name
- NCT03770780
- Testing
- SAGE-718
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Primary Biliary Cholangitis
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
- Trial name
- NCT03394924
- Testing
- EDP-305 1 mg, EDP-305 2.5 mg
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 68 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Acute Inflammatory Response to Non-antigenic Stimulus
Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide
A Phase 1a, randomized, placebo controlled, two-way crossover study is to determine the effect of inhaled MMI-0100 compared to placebo following LPS challenge on inflammatory markers.
- Trial name
- LPS (NCT02515396)
- Testing
- MMI-0100
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Moerae Matrix, Inc.
Healthy Volunteers
Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity
To evaluate the changes in serum aldosterone and plasma renin activity on Day 0 and on Days 1 and 10 after administration of 100 mg of eplerenone daily for 10 days.
- Trial name
- NCT00990223
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Candidemia, Invasive Candidiasis
Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial
CanTEN is a multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority phase 4 trial investigating a shortened treatment duration in patients with uncomplicated candidemia.
- Trial name
- CanTEN (NCT07788586)
- Testing
- Caspofungin only within the study, Caspofungin for 3 days within the study
- Where
- 24 sites in Germany
- Volunteers
- 420 people
- Sponsor
- Oliver Cornely, MD
Endotoxemia, Inflammation
Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive Function
Short-chain fatty acids (SCFAs) are substances produced by gut bacteria when they ferment dietary fiber. They can act as signals between the gut and the brain and may help regulate the body's immune and stress responses.
- Conditions
- Endotoxemia, Inflammation, Executive Function (Cognition)
- Trial name
- NCT07713641
- Testing
- Short-Chain Fatty Acid Colon-Delivery Capsules, Lipopolysaccharide (LPS)
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Diabetes Mellitus, Type 2, Hypoglycemia
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about how tirzepatide affects the body's response to low blood sugar (hypoglycemia). The study is open to participants with type 2 diabetes.
- Trial name
- NCT04050553
- Testing
- Tirzepatide
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Migraine
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged…
- Trial name
- NCT00617695
- Testing
- Zolmitriptan
- Volunteers
- 247 people
- Sponsor
- Impax Laboratories, LLC
Bacteremia
Alcohol Locks for the Prevention of Tunneled Catheter-related Infections
In modern-day medicine, the use of central venous catheters has become unavoidable. However, their use does not come without risk.
- Trial name
- NCT00122642
- Testing
- Alcohol-lock
- Where
- Netherlands
- Volunteers
- 440 people
- Sponsor
- Erasmus Medical Center
Bladder Cancer
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
Phase I/II study: Phase 1 is an open-label, safety study, patients who previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose…
- Trial name
- NCT02010203
- Testing
- HS-410, BCG
- Where
- 19 sites in United States
- Volunteers
- 104 people
- Sponsor
- Heat Biologics
Crohn's Disease
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease
- Trial name
- NCT00152490
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 604 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as baricitinib in participants with moderately to severely active rheumatoid arthritis who have had an inadequate response to…
- Trial name
- NCT02265705
- Testing
- Baricitinib
- Where
- 30 sites in Argentina, Brazil and 1 more
- Volunteers
- 290 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs.
- Trial name
- NCT04333771
- Testing
- SHR0302
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder…
- Trial name
- VENTURA-7 (NCT06514742)
- Testing
- Aticaprant
- Where
- 84 sites in United States, Belgium and 7 more
- Volunteers
- 101 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Dysthymia
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression
- Trial name
- NCT03761030
- Testing
- L-DOPA
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- New York State Psychiatric Institute
Herpes Zoster, Fibrosis
Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™
Study Design: Double-blinded, placebo controlled study of the efficacy of Zostavax in cirrhosis. Subjects will receive either Zostavax or placebo and will be followed for four months.
- Trial name
- NCT02958345
- Testing
- Zostavax
- Volunteers
- 28 people
- Sponsor
- Tulane University
Hypertension, Stress, Psychological
Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress
High blood pressure, or hypertension, is a serious problem in the African-American (AA) population which affects nearly 7 of every 10 AAs in our area.
- Conditions
- Hypertension, Stress, Psychological, Blood Pressure
- Trial name
- NCT02431936
- Testing
- Prazosin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Augusta University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.